Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Stock Short Interest Report for October

Daiichi Sankyo logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Short interest plunged 81.8% to 19,178 shares as of October 15, down from 105,501 shares on September 30. Short interest represented approximately 0.0% of shares outstanding, with a days-to-cover ratio of 0.1.
  • Analyst sentiment was negative: Jefferies downgraded Daiichi Sankyo to “Hold,” while Zacks Research cut its rating to “Strong Sell.” The consensus rating was “Reduce.”
  • The stock opened at $17.91, near its 50-day and 200-day moving averages. In its latest quarter, Daiichi Sankyo reported $0.24 in EPS versus a $0.25 estimate but exceeded revenue expectations with $3.61 billion.
  • Five stocks we like better than Daiichi Sankyo.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) was the recipient of a significant drop in short interest in October. As of October 15th, there was short interest totaling 19,178 shares, a drop of 81.8% from the September 30th total of 105,501 shares. Based on an average daily trading volume, of 224,827 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the company's shares are short sold.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Jefferies Financial Group lowered shares of Daiichi Sankyo from a "buy" rating to a "hold" rating in a report on Thursday, July 30th. Zacks Research downgraded shares of Daiichi Sankyo from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 20th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Reduce".

View Our Latest Stock Analysis on Daiichi Sankyo

Daiichi Sankyo Price Performance

Daiichi Sankyo stock opened at $17.91 on Tuesday. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. Daiichi Sankyo has a 52-week low of $14.98 and a 52-week high of $26.80. The firm has a market cap of $33.37 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 1.90 and a beta of -0.11. The company's 50 day moving average is $17.82 and its two-hundred day moving average is $17.79.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%. The company had revenue of $3.61 billion for the quarter, compared to analysts' expectations of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, research analysts expect that Daiichi Sankyo will post 0.93 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Daiichi Sankyo Right Now?

Before you consider Daiichi Sankyo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daiichi Sankyo wasn't on the list.

While Daiichi Sankyo currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines